Anti Cancer Medicines

Product Details:

CarfilzomibInjection (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.

The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy (such as lenalidomide) and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.

Indication-

• For Intravenous
• Administration Only
• For intravenous Administratio only

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

Pomalidomide is sold by Celgene Inc., in the USA, under the brand name Pomalyst. Pomalidomide is a thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma (a type of blood cancer) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. Pomalidomide is available under the name of Pomalid and is available in 3 different powers which are as follows Pomalid 1MG, 2MG, and 4MG.

Request
Callback

Product Details:

• Pemetrexed For Injection injection is used in the treatment of a type of lung cancer called non-squamous non-small cell lung cancer and in the treatment of another cancer called malignant pleural mesothelioma (a type of cancer that originates from the
• lining of the various organs of the body).
• Pemetrexed For Injection injection belong to class of chemotherapy drugs called folate antimetabolites. It disrupts certain metabolic processes essential for cancer cell replication and multiplication.
• To be diluted prior to intravenous administration
• For I.V Infusion Only

Request
Callback

Product Details:

Geftinib 250 mg is used to treat adults with non-small cell lung cancer (locally advanced or distance spread [metastasis]).
Geftinib 250 mg blocks a protein called ‘epidermal growth factor receptor’ (EGFR) which is involved in the growth and spread of cancer cells.

Request
Callback

Product Details:

• Azacitidine For Injection is used to treat a group of blood/bone marrow disorders (myelodysplastic syndromes-MDS) in which the bone marrow does not produce enough healthy blood cells. People with MDS usually have problems such as infections, anemia, and easy bleeding/bruising. Azacitidine is a chemotherapy drug.
• It works by helping your bone marrow grow normal blood cells so you will need fewer blood transfusions. Azacitidine also kills abnormal blood cells that have grown too fast and do not work properly.

Request
Callback

Product Details:

Cabazitaxel Injection is an anticancer drug administered usually in combination with steroid medications like prednisone or prednisolone. Cabazitaxel belongs to a group of medications called as taxanes. It acts by stopping the multiplication of cancer cells, ultimately reducing its growth and spread in the body, the treatment of prostate cancer (cancer of the gland in men situated below bladder) that has spread to other parts of the body after the failure of previous anticancer therapies.

Request
Callback

Product Details:

• Zoledronic Acid Injection IP bone is used to treat thinning and weakening of the bone (osteoporosis) and to prevent bone complications, e.g. fractures, in adult patients due to spread of cancer from other organs to .
• Zoledronic Acid Injection IP belongs to a class of drugs known as bisphosphonates. It works by slowing bone breakdown, increasing bone density (thickness), and decreasing the amount of calcium released from the bones into the blood.
• For Intravenous Infusion Sterile, Lyophilized

Request
Callback

Product Details:

Melphalan Tablets IPis used to treat multiple myeloma (a type of blood cancer), ovarian and breast cancer.
It works by stopping or slowing down the growth and spread of cancer cells in the body.

Request
Callback

Product Details:

Imatinib Capsules IP tablet is used in the treatment of blood cancers, bone marrow disorders, skin cancer and certain tumours of the stomach and the digestive tract.
Imatinib Mesylate belongs to a class of medications called kinase inhibitors. It works by preventing abnormal protein activity which signals cancer cells to multiply and spread across the body, thus inhibiting the growth of these abnormal cells.

Request
Callback

Product Details:

• Rasburicase Injection is a urate-oxidase enzyme. When chemotherapy is given, cancer cells are destroyed, releasing large amounts of uric acid into the blood. Rasburicase works by allowing uric acid to be more easily removed from the body by the kidneys.
• It is used for preventing high blood levels of uric acid from occurring in patients with certain types of cancer (eg, leukemia, lymphoma, solid malignant tumors) who are receiving cancer chemotherapy treatment.

Request
Callback

Product Details:

To meet the huge market demands, we are involved in offering a wide assortment of Lapatinib Tablet (Tykerb 250 Mg Tab). The offered Tykerb 250 Mg Tab (Lapatinib) is extensively used in combination with another anticancer medication to treat advanced or metastatic and it is very effective.

Features:

• Affordable rate
• Reliable
• Safe to consume

Request
Callback

Additional Information:

• Item Code: ONCLG010
• Port of Dispatch: Mumbai
• Production Capacity: 1000 Pieces
• Delivery Time: 3-4 days

Product Details:

• Pazopanib Tablets is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.
• The medication is used to treat clear cell variant renal cell carcinoma.
• The treatment phase is continuing treatment beyond 3-months.
• The patient has been issued an authority prescription for pazopanib
• The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST)
• This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition.

It has also demonstrated initial therapeutic properties in patients with ovarian and non-small cell lung cancer, though plans to apply to the EMA for a variation to include advanced ovarian cancer have been withdrawn and a license will not be sought in any country.

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

• Ceritinib Hard Gelatin Capsules is an aplastic lymphoma kinase (ALK)-positive inhibitor primarily used for the treatment of metastatic NSCLC. Previously, it was only indicated for patients who had developed resistant to crizotinib, another ALK-positive inhibitor, but has since had its usage expanded to serve as a primary option for metastatic NSCLC.

Ceritinib (trade name Zykadia) is a prescription-only drug used for the treatment non-small cell lung cancer (NSCLC). It was developed by Novartis and received FDA approval for use in April 2014. It is available as a 150 mg capsule with a one-time daily dosing requirement of 750 mg for NSCLC.

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

• We are offering Erlotinib Tablets IP 150 mg which is a Kinase inhibitor which is primarily used to treat cell lung cancer, or pancreatic cancer when combined with a certain other medications. It works by inhibiting growth to adjacent tissues in the body so that the cancerous cells slow down, allowing the patient a better environment to recover and fight cancer naturally.

Dosage and Administration:

• Typically, an adult patient will be instructed to take between 100mg and 150mg of Erlonat (Erlotinib), at least 1 hour before any meals or snacks and 2 hours after. Unless otherwise instructed, you should always swallow each tablet whole without chewing, crushing, splitting, or dissolving the tablet in liquid. Wash tablets down with full glass of water.

Request
Callback

Additional Information:

• Item Code: ONCLG009
• Pay Mode Terms: L/C (Letter of Credit),D/A,D/P,Other
• Port of Dispatch: Mumbai
• Production Capacity: 1000 Pieces
• Delivery Time: 3-4 days

Product Details:

We are offering Sorafenib Tablets  which are a cancer (chemotherapeutic) medication. Sorafenat Tablets interfere with the growth and spread of cancer cells in the body. Sorafenat Tablets is used to treat a type of kidney cancer called advanced renal cell carcinoma. It is also used to treat liver cancer. Sorafenat Tablets may also be used for purposes not listed in this medication guide.Do not use Sorafenat Tablets if you are pregnant. It could harm the unborn baby. Use effective birth control while you are using this medication and for at least 2 weeks after your treatment ends, whether you are a man or a woman.

Precautions & Warnings:

• Should not be taken without consulting the doctor if the patient ever had pulmonary fibrosis (scarring of the lungs), or liver or kidney disease
• Not recommended if the patient is allergic to the medicine or any of its constituents
• Kindly notify the doctor immediately, if allergic reactions (difficulty breathing, closing of the throat, swelling of the lips, tongue, or face; or hives), lung problems, liver problems, eye problems, severe nausea, vomiting, loss of appetite, or diarrhea during treatment are noticed
• Doctor consultation recommended for pregnant women or for those who are breast feeding their child

Overdose:

• Symptoms like diarrhea and rash

Side effects:

• Get emergency medical help if you have any of these signs of an allergic reaction to Sorafenat Tablets: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using Soranib Tablets and call your doctor at once if you have a serious side effect such as:

• Rash, blisters, oozing, or severe pain in the palms of your hands or the soles of your feet;
• Mouth sores;
• Black or bloody stools, coughing up blood or vomit that looks like coffee grounds;
• Pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
• Easy bruising, unusual bleeding (nose, mouth, , or rectum), purple or red pinpoint spots under your skin;
• Chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;
• Dry cough, wheezing.

Request
Callback

Additional Information:

• Item Code: ONCOLOGY1
• Port of Dispatch: Mumbai
• Production Capacity: 1000 Pieces
• Delivery Time: 3-4 days

Product Details:

Decitabine Lyophilized for Injection is indicated for treatment of patients with myelodysplastic syndromes (MDS) including Previously treated and untreated De novo and secondary All French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) Intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.

Request
Callback

Product Details:

Bortezomib for Injection is used to treat certain types of cancer such as multiple myeloma (a cancer of the cells of the immune system in the bone marrow) and mantle cell lymphoma (a cancer of the cells of the immune system affecting the lymph nodes).
It works by stopping or slowing down the growth and spread of cancer cells in the body.

Request
Callback

Product Details:

• Ruxolitinib (trade names Jakavi) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera (PCV) when there has been an inadequate response to or intolerance of hydroxyurea.
• Ruxolitinib is a janus kinase inhibitor with selectivity for subtypes JAK1 and JAK2 of this enzyme. Ruxolitinib inhibits dysregulated JAK signaling associated with myelofibrosis. JAK1 and JAK2 recruit signal transducers and activators of transcription (STATs) to cytokine receptors leading to modulation of gene expression.

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.

It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users.

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

Secukinumab, trade name Cosentyx, is a human IgG1 monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.
It is used to treat psoriasis, ankylosing spondylitis, and psoriatic arthritis. It is given by subcutaneous injection and is sold in a pre-filled syringe or autoinjector that can be used at home and as a lyophilized powder for use in hospitals and clinics.
Secukinumab was not tested in pregnant women animal studies did not show harm at relevant doses. The FDA advises that the drug should be used in pregnant women only if the risk to the fetus justifies the potential benefit, the EMA advises that women should not become pregnant while taking it.

Precautions-

• Store in 2 to 8 DegC (In a Refrigerator)
• Protect From Light
• Store in the Original Package
• Keep Out of Reach and Sight Of Children

Request
Callback

Product Details:

SABRIL (vigabatrin) is an oral antiepileptic drug and is available as white film-coated 500 mg tablets and as a white to off-white granular powder for oral solution in packets of 500 mg.

The chemical name of vigabatrin, a racemate consisting of two enantiomers, is (±) 4 -amino-5-hexenoic acid.
Each SABRIL tablet contains 500 mg of vigabatrin. 

Indications

Refractory Complex Partial Seizures (CPS)SABRIL is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss .SABRIL is not indicated as a first line agent for complex partial seizures.

Infantile Spasms (IS)SABRIL is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss

AdministrationSABRIL is given orally with or without food.

Dosing
Refractory Complex Partial SeizuresAdults (Patients 17 Years of Age and Older)

Treatment should be initiated at 1000 mg/day (500 mg twice daily). Total daily dose may be increased in 500 mg increments at weekly intervals, depending on response. The recommended dose of SABRIL in adults is 3000 mg/day (1500 mg twice daily). A 6000 mg/day dose has not been shown to confer additional benefit compared to the 3000 mg/day dose and is associated with an increased incidence of adverse events.

In controlled clinical studies in adults with complex partial seizures, SABRIL was tapered by decreasing the daily dose 1000 mg/day on a weekly basis until discontinued

Pediatric (Patients 10 to 16 Years of Age)Treatment is based on body weight as shown in Table 1. Treatment should be initiated at a total daily dose of 500 mg/day (250 mg twice daily) and may be increased weekly in 500 mg/day increments to a total maintenance dose of 2000 mg/day (1000 mg twice daily). Patients weighing more than 60 kg should be dosed according to adult recommendations.

In patients with refractory complex partial seizures, SABRIL should be withdrawn if a substantial clinical benefit is not observ ed within 3 months of initiating treatment. If, in the clinical judgment of the prescriber, evidence of treatment failure become s obvious earlier than 3 months, treatment should be discontinued at that time

Infantile SpasmsThe initial daily dosing is 50 mg/kg/day given in two divided doses (25 mg/kg twice daily); subsequent dosing can be titrated by 25 mg/kg/day to 50 mg/kg/day increments every 3 days, up to a maximum of 150 mg/kg/day given in 2 divided doses (75 mg/kg twice daily)

Storage And Handling

Store at 20 to 25°C (68 to 77°F). 

Request
Callback

Additional Information:

• Production Capacity: 10000 boxes
• Delivery Time: 7 working days
• Packaging Details: one box has 10 strips of 10 tablets

Product Details:

Sorafenib Tosylate Tablets is used in the treatment of liver cancer (hepatocellular carcinoma), advanced stage kidney cancer (advanced renal cell carcinoma) and thyroid cancer (differentiated thyroid carcinoma) when standard therapy has failed or is considered unsuitable.
Sorafenib Tosylate Tablets belongs to the class of drugs called multikinase inhibitors. It slows down the rate of growth of cancer cells by blocking the action of an abnormal protein that signals cancer cells to multiply. It cuts down the blood supply to the cancer cells and stops their growth and proliferation.

Request
Callback

Product Details:

Request
Callback

Product Details:

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai

Product Details:

Lenvima (Lenvatinib) is a prescription medicine that is used to treat certain kinds of cancer.

1) Thyroid cancer: Lenvima is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer, that can no longer be treated with radioactive iodine and is progressing.

2) Kidney cancer: Lenvima is used along with another medicine, everolimus, to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicine.

Request
Callback

Product Details:

• Alecensa Hard Capsules is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and whose type of NSCLC is caused by an abnormal anaplastic lymphoma kinase (ALK) gene. Your healthcare provider will perform a test to make sure that ALECENSA is right for you.
• It is not known if ALECENSA is safe and effective in children.
• Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).
• It was granted an accelerated approval by the US Food and Drug Administration (FDA) in December 2015 to treat patients with advanced ALK-positive NSCLC whose disease worsened after, or who could not tolerate, treatment with crizotinib (Xalkori). (This was converted into a full approval in Nov 2017).
• It got a conditional approval by the European Medicines Agency in February 2017 for the same indication. This means that additional studies are awaited to confirm a positive benefit-risk-ratio.
• There are no contraindications under the US approval. The European approval only has the default remark about hypersensitivity being a contraindication
  In November 2017 the FDA approved alectinib for the first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer. This based on the phase 3 ALEX trial comparing it with crizotinib.

Request
Callback

Additional Information:

• Pay Mode Terms: L/C (Letter of Credit),T/T (Bank Transfer),D/P,D/A
• Port of Dispatch: Mumbai
• Delivery Time: 8-10 days

Product Details:

Osimeritnib 80 mg Tablets is the generic name for the trade drug Tagrisso(TM). In some cases, health care professionals may use the trade name Tagrisso(TM) when referring to the generic drug name osimertinib. Osimertinib is a targeted therapy. It is an oral EGFR Kinase inhibitor. It is used for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by FDA-approved test, who have progressed on or after EGFR TKII therapy.

Request
Callback

Product Details:

Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitorapproved for the treatment of imatinib-resistant chronic myelogenous leukemia. Structurally related to imatinib, it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells. Nilotinib was developed by Novartis and is sold under the trade name Tasigna.

Request
Callback

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai